Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products

Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products

The antitumor activity of adoptive T cell therapies (ACT) is highly dependent on the expansion, persistence, and continued activity of adoptively transferred cells. Clinical studies using ACTs have revealed that products that possess and maintain less differentiated phenotypes, including memory and...

Full description

Bibliographic Details
Main Authors: Charlotte O’Brien Gore, Amy Billman, Suchete Hunjan, Jayne Colebrook, Desmond Choy, Wilson Li, Jack Haynes, Jennifer Wade, Emily Hobern, Louisa McDonald, Sophie Papa, Martijn Brugman, Shahram Kordasti, Claudia Montiel-Equihua
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Molecular Therapy: Oncolytics
Subjects:
non-small cell lung cancer
immunotherapy
cancer immunotherapy
CAR-T cells
adoptive T cell therapy
cell therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770523000980

Internet

http://www.sciencedirect.com/science/article/pii/S2372770523000980

Similar Items